News round-up for 5-9 December by DDW Digital Content Editor Diana Spencer.
‘Teamwork makes the dream work’ this week, with the launch of new partnerships to further the development of precision drugs in neurodevelopmental disorders, lung cancer and rare paediatric diseases.
The benefits of collaboration have also been seen in the announcement of positive trial data for Jardiance, a type 2 diabetes treatment created by an alliance between Boehringer Ingelheim and Eli Lilly, while various research groups team up to bring us closer to a HIV vaccine.
The top stories:
Partnership hopes to advance precision drug development
A new partnership between industry and three rare disease foundations has formed with the goal of accelerating the development of precision drugs to treat rare neurodevelopmental disorders.
Encouraging trial findings renew hope for HIV vaccine
While scientists have struggled in the past to create an effective vaccine against HIV, a novel vaccine design strategy shows new promise, according to data from a first-in-human clinical trial.
International consortium launches €12.8 million lung cancer project
Irish biotech company OmniSpirant and French biotech EVerZom have joined other partners to launch INSPIRE, a €12.8 million lung cancer project funded by Horizon Europe.
Positive Phase III trial data for SGLT2 inhibitor in type 2 diabetes
A Phase III trial has demonstrated that Jardiance (empagliflozin) is the first SGLT2 inhibitor to show a reduction in blood sugar levels in children and adolescents with type 2 diabetes.
European coalition to accelerate research into 7000 rare diseases
The ‘Rare Disease Moonshot’, a new initiative to boost research and development into rare and paediatric diseases, has launched at the European Health Summit.
